Mitochondrial transfer in the HSC–HCC–macrophage network shapes hepatocellular carcinoma progression

L La Zhang (Department of Critical Care Medicine of The First Affiliated Hospital, College of Basic Medical Sciences, Chongqing Medical University) C Cong Ren (Institute of Chemical Biology and Nanomedicine, State Key Laboratory of Chemo and Biosensing, Hunan Provincial Key Laboratory of Biomacromolecular Chemical Biology, College of Chemistry and Chemical Engineering) M Miao He X Xinyu Chen H Hongqing Liu (Department of Bioinformatics, Chongqing Medical University) Y Yilin Liu J Jing Luo Z Zhenghang Li (Department of Critical Care Medicine of The First Affiliated Hospital, College of Basic Medical Sciences, Chongqing Medical University) J Jianwei Wang W Wenjun Miao (Department of Immunology, School of Basic Medical Sciences, Chongqing Medical University) Q Qiling Peng (Molecular Medicine and Cancer Research Center, College of Basic Medical Sciences, Chongqing Medical University) N Ning Jiang (Sorbonne Université, CNRS , , ,)

Abstract

Mitochondrial crosstalk between tumor cells and components of the tumor microenvironment (TME) is a critical yet underexplored mechanism driving hepatocellular carcinoma (HCC) progression. Here, we demonstrate that in HCC, mitochondria can be transferred from hepatic stellate cells to cancer cells via tunneling nanotubes (TNTs), supplying essential energy for tumor growth. Simultaneously, cancer cells offload damaged mitochondria to macrophages through extracellular vesicles (EVs), facilitating their clearance and promoting tumor development. To disrupt this mitochondrial exchange, we developed a responsive liposomal nanocarrier (L&G@Lipo PPV ) coencapsulating L-778123 and GW4869 to simultaneously inhibit TNT-mediated and vesicle-mediated mitochondrial transfer. This work provides the first comprehensive evidence of mitochondrial transfer dynamics in the TME, with tumor cells as the central hub, and highlights L&G@Lipo PPV as an innovative and effective strategy to block mitochondrial crosstalk. Our findings address critical challenges of drug solubility and delivery, offering a rational approach to reprogram the TME and suppress liver cancer progression.

Article Details

Volume / Issue Vol. 123, Issue 6
Published February 10, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (12)

L

La Zhang

Department of Critical Care Medicine of The First Affiliated Hospital, College of Basic Medical Sciences, Chongqing Medical University

C

Cong Ren

Institute of Chemical Biology and Nanomedicine, State Key Laboratory of Chemo and Biosensing, Hunan Provincial Key Laboratory of Biomacromolecular Chemical Biology, College of Chemistry and Chemical Engineering

M

Miao He

X

Xinyu Chen

H

Hongqing Liu

Department of Bioinformatics, Chongqing Medical University

Y

Yilin Liu

J

Jing Luo

Z

Zhenghang Li

Department of Critical Care Medicine of The First Affiliated Hospital, College of Basic Medical Sciences, Chongqing Medical University

J

Jianwei Wang

W

Wenjun Miao

Department of Immunology, School of Basic Medical Sciences, Chongqing Medical University

Q

Qiling Peng

Molecular Medicine and Cancer Research Center, College of Basic Medical Sciences, Chongqing Medical University

N

Ning Jiang

Sorbonne Université, CNRS , , ,